Dysregulation of the CDK4/6 pathway leads to increased cell proliferation, making inhibition of these kinases a promising approach to cancer treatment [22], with some CDK4/6 inhibitors currently approved for the treatment of breast cancer [23]. This evidence concerns the gene CDK4 and cancer.